BioCentury | Jun 6, 2020
Product Development

Failing in master protocol casts fresh doubt on hydroxychloroquine even as WHO restarts trial

...had reported no significant association between COVID-19 mortality and pre-existing treatment with ACE inhibitors or angiotensin receptor...
BioCentury | Jul 19, 2019
Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

...same pharmacological class with mortality and safety data. For example, safety profiles of ACE inhibitors, angiotensin receptor...
BioCentury | Sep 19, 2017
Clinical News

Limited benefit for beta blockers in combo therapy

...90,869 Medicare beneficiaries ages 65 and older who were prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor...
...associated with higher mortality. Mary Romeo Monash University University of North Carolina at Chapel Hill Adrenergic receptor beta 2 (ADRB2) Angiotensin receptor Angiotensin-converting...
BioCentury | Sep 12, 2016
Clinical News

Sparsentan: Phase II data

...N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567 ) Business: Renal Molecular target: Angiotensin receptor...
BioCentury | May 2, 2016
Company News

Novartis sales and marketing update

...ejection fraction and whose heart failure is not controlled by angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor...
BioCentury | Apr 27, 2016
Company News

NICE backs Novartis' Entresto

...ejection fraction, and whose heart failure is not controlled by angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor...
BioCentury | Apr 11, 2016
Clinical News

Sparsentan: Completed Phase II enrollment

...N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567 ) Business: Renal Molecular target: Angiotensin receptor...
BioCentury | Nov 16, 2015
Clinical News

Aclerastide: Phase III discontinued

...radiation dermatitis. Derma Sciences Inc. (NASDAQ:DSCI), Princeton, N.J. Product: Aclerastide (DSC127) Business: Dermatology Molecular target: Angiotensin receptor...
BioCentury | Nov 16, 2015
Product Development

Myo my

...and p=0.190). The improvements came on top of background therapies including angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor...
...SOC, or onto Entresto or Corlanor, which could become part of SOC. Entresto combines the angiotensin receptor...
BioCentury | Jun 11, 2015
Translation in Brief

Taming toxins for pain

Scientists at the Pasteur Institute have created a pain therapeutic from an ulcer-causing toxin by removing a functional group responsible for its toxic properties and leaving intact the core molecule with analgesic and anti-inflammatory activity....
Items per page:
1 - 10 of 149